Paper Details

  1. Home
  2. Paper Details

A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.

Author: DrewJanice, GlaserDee Anna, GreenLawrence, HebertAdelaide A, MamelokRichard D, NastAlexander, PariserDavid M, QuiringJohn, WerschlerWilliam P

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Daily long-term application of glycopyrronium tosylate for up to 48 weeks was generally well tolerated and efficacy was maintained. The Hyperhidrosis Disease Severity Scale responder rate was 63.2% at week 44. No new safety signals emerged.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Glycopyrronium tosylate is a topical anticholinergic approved in the USA for primary axillary hyperhidrosis in patients aged ≥ 9 years (Qbrexza™ [glycopyrronium] cloth, 2.4%). OBJECTIVE: This 44-week open-label extension study assessed glycopyrronium tosylate safety and descriptive effi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687675/

データ提供：米国国立医学図書館（NLM）

Treating Axillary Hyperhidrosis: A Long-Term Perspective

Excessive sweating, also known as hyperhidrosis, can be a distressing condition, affecting self-confidence and social interactions. Finding effective and well-tolerated treatments for this condition is crucial for improving patients' quality of life.

This research examines the long-term safety and efficacy of topical glycopyrronium tosylate, an anticholinergic medication, in treating primary axillary hyperhidrosis. The study involved a 44-week open-label extension following a double-blind phase III trial, demonstrating the medication's sustained efficacy and favorable safety profile over time. Imagine a desert oasis where a sustainable water source provides long-lasting benefits – in this case, topical glycopyrronium tosylate offering long-term relief from hyperhidrosis.

A Promising Treatment for Hyperhidrosis

This research suggests that topical glycopyrronium tosylate can effectively manage primary axillary hyperhidrosis over an extended period. The study highlights the medication's favorable safety profile and enduring efficacy.

Managing Hyperhidrosis: Seeking Professional Help

This research emphasizes the importance of seeking professional help when dealing with hyperhidrosis. A qualified healthcare professional can provide a proper diagnosis and recommend the most appropriate treatment options.

Dr. Camel's Conclusion

This research offers a refreshing oasis in the desert of hyperhidrosis treatment, highlighting the potential of topical glycopyrronium tosylate for long-term management of this condition. By embracing these innovations and seeking professional guidance, we can help patients find relief and improve their quality of life.
Date :
  1. Date Completed 2020-01-21
  2. Date Revised 2020-02-25
Further Info :

Pubmed ID

31111409

DOI: Digital Object Identifier

PMC6687675

Related Literature

Article Analysis
・Effects of glycopyrronium topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.